- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06441331
Studio di fase I per determinare la dose e valutare la farmacocinetica della terapia con lutezio Lu 177 edotreotide in partecipanti pediatrici con tumori SSTR-positivi (KinLET)
Uno studio interventistico di fase I, multicentrico, in aperto, per determinare la dose e valutare la farmacocinetica (PK) e la sicurezza della terapia radiofarmaceutica mirata (RPT) con lutezio Lu 177 edotreotide come monoterapia o seguendo lo standard di cura (SoC) per il trattamento della somatostatina Tumori positivi al recettore nella popolazione pediatrica (KinLET).
The purpose of the study is to determine the appropriate pediatric dosage and evaluate the pharmacokinetics (PK) and safety of Lutetium Lu 177 Edotreotide Targeted Radiopharmaceutical Therapy (RPT) as a monotherapy or following standard of care (SoC) in participants ≥2 to <18 years of age with somatostatin receptor (SSTR)-positive tumors.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Determine the dose, pharmacokinetics and safety of Lutetium Lu 177 Edotreotide as monotherapy or following sequential standard of care in pediatric participants with recurrent, progressive or refractory NET, CNS, lymphoma and other solid tumors that express SSTRs by immunohistochemistry and demonstrate uptake by somatostatin receptor imaging. Lutetium Lu 177 Edotreotide will be given intravenously once every 8 weeks for a total of up to 6 doses over an average of 48 weeks in participants aged 2-18 years.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Serhii Melnyk, MD
- Email: kinlet@itm-radiopharma.com
Backup dei contatti dello studio
- Nome: Pia Zehkorn
- Numero di telefono: +4989 32989866000
- Email: kinlet@itm-radiopharma.com
Luoghi di studio
-
-
-
Marseille, Francia, 13005
- Reclutamento
- CHU de Marseille - Hôpital de la Timone
-
Contatto:
- Nicolas Andre, Prof
- Email: nicolas.andre@ap-hm.fr
-
Villejuif, Francia, 94800
- Reclutamento
- Gustave Roussy Cancer Campus
-
Contatto:
- Charlotte Rigaud, Dr
- Email: charlotte.rigaud@gustaveroussy.fr
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hospital Universitario Vall d'Hebron - Oncología Médica
-
Contatto:
- Lucas Moreno, Dr.
- Email: lucas.moreno@vallhebron.cat
-
Madrid, Spagna, 28009
- Reclutamento
- Hospital General Universitario Gregorio Marañón
-
Contatto:
- Cristina Mata Fernandez, Dr
- Numero di telefono: +34 915290037
- Email: cristina.mata@salud.madrid.org
-
-
-
-
California
-
Palo Alto, California, Stati Uniti, 94304
- Reclutamento
- Lucile Packard Children's Hospital at Stanford
-
Contatto:
- Raya Hamad Saab, Prof
- Numero di telefono: (650) 497-8953
- Email: rsaab@stanford.edu
-
San Francisco, California, Stati Uniti, 94158
- Reclutamento
- UCSF Benioff Children's Hospital
-
Contatto:
- Kieuhoa T. Vo, MD
- Numero di telefono: 415-476-3831
- Email: kieuhoa.vo@ucsf.edu
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45229
- Reclutamento
- Cincinnati Children's Hospital Medical Center
-
Contatto:
- Brian K. Turpin, Do
- Email: brian.turpin@cchmc.org
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104-4319
- Reclutamento
- The Children's Hospital of Philadelphia (CHOP)
-
Contatto:
- Theodore W. Laetsch, MD
- Email: laetscht@chop.edu
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- University of Texas - MD Anderson Cancer Center
-
Contatto:
- David McCall, MD
- Email: dmccall1@mdanderson.org
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- Participants aged ≥ 2 years and < 18 years
- Confirmed diagnosis somatostatin receptor-positive (SSTR-positive) disease.
- Tumor which is relapsed or is refractory to at least one line of previous therapy
- Positive SSTR protein expression confirmed by immunohistochemistry of a tumor histology sample
- Radioactivity uptake within the primary tumor or metastatic tumor sites measured by locally available SRIs ( 111In-based, 99mTc-based, or 68Ga-based SSTR single-photon emission computed tomography (SPECT)/ computed tomography (CT) or positron emission tomography (PET)/CT imaging, which is higher than the liver uptake)
- Participants must have recovered from the acute treatment related toxicities (defined as ≤ grade 1 if not defined in eligibility criteria, excluding alopecia, stable treated electrolyte abnormalities on replacement and stable treated hypothyroidism) of all prior treatment modality prior to entering this trial
- In case of sequential treatment followed by SoC or prior therapy, washout period applies before starting targeted RPT
Screening Consent Participant/legal guardian is willing to sign a screening consent. The screening consent is to be obtained according to institutional guidelines. Assent, when appropriate, will be obtained according to institutional guidelines.
Key Exclusion Criteria:
- Known hypersensitivity to Lutetium Lu 177 Edotreotide, DOTA/Edotreotide, or excipients
- Previous history of acute leukemia unless in remission for at least two years
- Extensive bone/bone marrow involvement as per Investigator's judgement unless peripheral blood stem cells (PBSC) are available at a minimum of 2.5x106 CD34+ cells/kg
- Patients who have received previous systemic targeted RPT
- Previous treatment with metaiodobenzyl guanidine (MIBG) if the predicted overall exposure is expected to exceed 2 Gy (gray) to the bone marrow or 23 Gy to the kidney.
- Previous treatment with external beam radiation therapy (EBRT) if the predicted overall exposure is expected to exceed more than 2 Gy to the bone marrow or 23 Gy to the kidney.
- Previous treatment with oncologic immune vaccine or CAR-T cell therapy
- Bulky disease in the CNS
- Presence of severe renal, hepatic, electrolyte, cardiovascular, or hematological dysfunction
- Participants who have received a live-attenuated vaccine up to four weeks prior to enrolment
- Pregnant or breastfeeding women.
- Other known malignancies.
- Serious non-malignant disease.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Three sequential age cohorts
Arms are based upon age at enrollment. The opening of the 2nd and 3rd cohort will depend on the recruitment of at least four participants with dosimetry and safety data for cycle 1, in the previous cohort.
|
lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks
Altri nomi:
The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Pediatric Dosage
Lasso di tempo: a. Dosimetry assessments will be performed at multiple timepoints in cycle 1, 2 and 4. - b. Minimum of eight weeks after the first administration of Lutetium Lu 177 edotreotide
|
Pediatric dosage based on:
|
a. Dosimetry assessments will be performed at multiple timepoints in cycle 1, 2 and 4. - b. Minimum of eight weeks after the first administration of Lutetium Lu 177 edotreotide
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate
Lasso di tempo: At the end of Cycle 2 (each cycle is 28 days)
|
Assess preliminary anti-tumor activity by tumor type |
At the end of Cycle 2 (each cycle is 28 days)
|
|
PK and dosimetry
Lasso di tempo: Dosimetry assessments will be performed at multiple timepoints at Cycle 1, 2 and 4.
|
Lutetium Lu 177 edotreotide PK evaluation and tumor and target organ dosimetry |
Dosimetry assessments will be performed at multiple timepoints at Cycle 1, 2 and 4.
|
|
Rate of adverse events
Lasso di tempo: From treatment start until 33 days following the last dose of trial treatment or until the End of Last Treatment (EOLT) visit, whichever occurs later..
|
Safety evaluation of Lutetium Lu 177 edotreotide targeted RPT as monotherapy or following standard of care |
From treatment start until 33 days following the last dose of trial treatment or until the End of Last Treatment (EOLT) visit, whichever occurs later..
|
|
Overall Survival, Progression-Free Survival and Duration of Response
Lasso di tempo: Every 9 ± 3 weeks from enrollment until disease progression or for up to two years, whichever came first.
|
Additional preliminary efficacy evaluation of lutetium Lu 177 Edotreotide targeted RPT as monotherapy or following SoC |
Every 9 ± 3 weeks from enrollment until disease progression or for up to two years, whichever came first.
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Exploratory Endpoint: Quality of Life
Lasso di tempo: At enrollment, 18 days prior to cycles 2-6, four ± 3 weeks after targeted RPT.
|
Assess quality of life based on the adapted Quality of Life (QoL) scale (PedsQL TM 3.0 Cancer Module) |
At enrollment, 18 days prior to cycles 2-6, four ± 3 weeks after targeted RPT.
|
|
Exploratory Endpoint: Correlation between SSTR expression detected by immunohisto-chemistry and functional imaging
Lasso di tempo: No timeframe given.
|
Correlation of the expression level of SSTR immunohistochemistry in tumor biopsy or surgery samples and 111In-based, 99mTc-based, or 68Ga-based-based lesion uptake (regarding intensity/distribution) |
No timeframe given.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Roman Henkel, PhD, Director, Global Clinical Operations
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema nervoso
- Neoplasie per sede
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Malattie linfatiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Neoplasie del sistema nervoso
- Sarcoma
- Neoplasie, Connettivo e Tessuto Molle
- Tumori neuroectodermici, primitivi
- Neoplasie, tessuto muscolare
- Miosarcoma
- Malattie emiche e linfatiche
- Linfoma
- Tumori neuroendocrini
- Rabdomiosarcoma
- Tumori neuroectodermici, primitivi, periferici
- Neoplasie del sistema nervoso centrale
- Tumore neuroendocrino gastroopancreatico
- soluzione di aminoacido, glucosio ed elettroliti
- 177LU-Occtreotide, Dota (0) -Tyr (3)-
Altri numeri di identificazione dello studio
- ITM-1191-01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .